CHLORZOXAZONE | A207483 | ANDA REPOSITORY LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Pharmobedient Consulting, LLC FDA-2025-P-0344 Pharmobedient Consulting, LLC filed a suitability petition pursuant to section 505(j)(2)(C) of the FDC Act and 21 C.F.R. § 314.93 requesting that the FDA declare Chlorzoxazone Tablets, 125 mg suitable for submission in an ANDA, which differs in strength from the reference listed drug Paraflex (Chlor | Suitability | 2025-01-29 | Open | Pharmobedient Consulting |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.